
Shaping the future for young women facing breast cancer
Recent studies have refined current knowledge on how to better treat this patient population, taking care of their unique needs and expectations

Who benefits from immunotherapy for breast cancer?
Defining patients most likely to respond, a better understanding of the host–tumour immune axis and clinical trials for specific subtypes are key to extending success

What is the role of adjuvant immunotherapy in contemporary melanoma care?
Adjuvant immunotherapy is still actual despite heterogeneity on its accessibility in Europe and fast advances in neoadjuvant immunotherapy

Drug de-escalation in lung cancer: are we nearly there yet?
While strategies for drug de-escalation continue to be actively pursued, some challenges including insufficient funding of research still limit their applicability

Tumour-agnostic drug development is revolutionising precision oncology
While the field is rapidly evolving, regulatory shifts and greater access to tumour profiling are now needed to realise the full benefits for patients

Novel insights into combination therapy in metastatic castration-resistant prostate cancer
Final survival data from the TALAPRO-2 study support the use of a PARP inhibitor plus an androgen receptor pathway inhibitor

ctDNA and beyond to serve immunotherapy
Recent findings consolidate the role of liquid biopsy in the field, but prospective research is needed

Neoadjuvant immunotherapy sets a new standard in stage III melanoma
Next steps for research include personalising regimens and learning how to predict response and toxicity

Preventing the rise in obesity-related cancers in Asia
Long-term multisectoral preventive actions that take into account local requirements are needed

Translating cancer genome insights into practical clinical tools
Findings from complex statistical modelling can form the basis for easy-to-use precision diagnostic and risk-stratification tools to help inform management decisions